Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
Authors:
- Koji NagafujiKNKoji Nagafuji
- Toshihiro MiyamotoTMToshihiro Miyamoto
- Tetsuya EtoTETetsuya Eto
- Tomohiko KamimuraTKTomohiko Kamimura
- Shuichi TaniguchiSTShuichi Taniguchi
- Takashi OkamuraTOTakashi Okamura
- Eiichi OhtsukaEOEiichi Ohtsuka
- Takashi YoshidaTYTakashi Yoshida
- Masakazu HiguchiMHMasakazu Higuchi
- Goichi YoshimotoGYGoichi Yoshimoto
- Tomoaki FujisakiTFTomoaki Fujisaki
- Yasunobu AbeYAYasunobu Abe
Open Access
- 6 February 2013
- journal article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 6 (1) , 14
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is much more intensive than multi-agent combined chemotherapy, although allogeneic HSCT is associated with increased morbidity and mortality when compared with such chemotherapy. Minimal residual disease (MRD) status has been proven to be a strong prognostic factor for adult patients with Ph-negative ALL.Keywords
This publication has 39 references indexed in Scilit:
- Optimal therapy for acute lymphoblastic leukemia in adolescents and young adultsNature Reviews Clinical Oncology, 2011
- What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesBlood, 2008
- Chemotherapy or allografting for young adults with high-risk ALL?Blood, 2008
- Response: Chemotherapy or allografting for young adults with high-risk ALL?Blood, 2008
- Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center settingLeukemia, 2007
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyBlood, 2006
- Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemiaEuropean Journal of Haematology, 2006
- Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaBlood, 2006
- Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993Blood, 2005
- Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remissionBone Marrow Transplantation, 1998